Advertisement

Cancer Immunology, Immunotherapy

, Volume 61, Issue 11, pp 1917–1927 | Cite as

Annexin-V promotes anti-tumor immunity and inhibits neuroblastoma growth in vivo

  • Xiaocai Yan
  • Kara Doffek
  • Chaobo Yin
  • Michael Krein
  • Michael Phillips
  • Sonia L. Sugg
  • Bryon Johnson
  • Joel ShilyanskyEmail author
Original article

Abstract

The goal of the current study is to determine the effects of blocking phosphatidylserine (PS) on the growth of neuroblastoma in mice. PS, an anionic phospholipid restricted to the cytoplasmic surface of plasma membranes in most cells, is externalized to the surface of apoptotic cells. PS has been shown to induce immune tolerance to self-antigens. PS can also be found on the surface of live cells and in particular tumor cells. Annexin-V (AnV) is a protein that specifically binds and blocks PS. To determine the effects of blocking PS with AnV on tumor growth and immunogenicity, mice were inoculated with AGN2a, a poorly immunogenic murine neuroblastoma that expresses high level of PS on the cell surface. Survival and anti-tumor T cell response were determined. AGN2a were engineered to secrete AnV. Secreted protein effectively blocked tumor PS. 40 % of mice inoculated with AnV-expressing AGN2a cells survived free of tumor, whereas none of the mice inoculated with control cells survived (p = 0.0062). The benefits of AnV were lost when mice were depleted of T cells. The findings suggest that AnV could protect mice from tumor challenge through an immune mediated mechanism. Mice were then immunized with irradiated AnV-secreting or control cells, and challenged with wild-type AGN2a cells. AnV-secreting cell vaccine protected 80 % of mice from AGN2a challenge, while control cell vaccine prevented tumor growth in only 30 % of animals (p = 0.012). ELISPOT analysis demonstrated that AnV-secreting cell vaccine induced a greater frequency of interferon-gamma producing splenic T cells. T cells isolated from mice immunized with AnV-secreting but not control vaccine lysed AGN2a. In summary, AnV blocked PS, enhanced T cell mediated tumor immunity, and inhibited tumor growth.

Keywords

Phosphatidylserine Annexin-V T cell Tumor Neuroblastoma Tumor immunity 

Notes

Conflict of interest

The authors declare that they have no conflict of interest.

References

  1. 1.
    Van Mierlo GJ, Boonman ZF, Dumortier HM, den Boer AT, Fransen MF, Nouta J, van der Voort EI, Offringa R, Toes RE, Melief CJ (2004) Activation of dendritic cells that cross-present tumor-derived antigen licenses CD8 + CTL to cause tumor eradication. J Immunol 173(11):6753–6759PubMedGoogle Scholar
  2. 2.
    Ghiringhelli F, Apetoh L, Housseau F, Kroemer G, Zitvogel L (2007) Links between innate and cognate tumor immunity. Curr Opin Immunol 19(2):224–231PubMedCrossRefGoogle Scholar
  3. 3.
    Steitz J, Bruck J, Lenz J, Knop J, Tuting T (2001) Depletion of CD25(+) CD4(+) T cells and treatment with tyrosinase-related protein 2-transduced dendritic cells enhance the interferon alpha-induced, CD8(+) T-cell-dependent immune defense of B16 melanoma. Cancer Res 61(24):8643–8646PubMedGoogle Scholar
  4. 4.
    Handel-Fernandez ME, Cheng X, Herbert LM, Lopez DM (1997) Down-regulation of IL-12, not a shift from a T helper-1 to a T helper-2 phenotype, is responsible for impaired IFN-gamma production in mammary tumor-bearing mice. J Immunol 158(1):280–286PubMedGoogle Scholar
  5. 5.
    Barth RJ Jr, Mule JJ, Spiess PJ, Rosenberg SA (1991) Interferon gamma and tumor necrosis factor have a role in tumor regressions mediated by murine CD8 + tumor-infiltrating lymphocytes. J Exp Med 173(3):647–658PubMedCrossRefGoogle Scholar
  6. 6.
    Matsui S, Ahlers JD, Vortmeyer AO, Terabe M, Tsukui T, Carbone DP, Liotta LA, Berzofsky JA (1999) A model for CD8 + CTL tumor immunosurveillance and regulation of tumor escape by CD4 T cells through an effect on quality of CTL. J Immunol 163(1):184–193PubMedGoogle Scholar
  7. 7.
    Kaplan DH, Shankaran V, Dighe AS, Stockert E, Aguet M, Old LJ, Schreiber RD (1998) Demonstration of an interferon gamma-dependent tumor surveillance system in immunocompetent mice. Proc Natl Acad Sci USA 95(13):7556–7561PubMedCrossRefGoogle Scholar
  8. 8.
    Dunn GP, Bruce AT, Sheehan KC, Shankaran V, Uppaluri R, Bui JD, Diamond MS, Koebel CM, Arthur C, White JM, Schreiber RD (2005) A critical function for type I interferons in cancer immunoediting. Nat Immunol 6(7):722–729PubMedCrossRefGoogle Scholar
  9. 9.
    Rousseau RF, Brenner MK (2005) Vaccine therapies for pediatric malignancies. Cancer J 11(4):331–339PubMedCrossRefGoogle Scholar
  10. 10.
    Smyth MJ, Godfrey DI, Trapani JA (2001) A fresh look at tumor immunosurveillance and immunotherapy. Nat Immunol 2(4):293–299PubMedCrossRefGoogle Scholar
  11. 11.
    Rabinovich GA, Gabrilovich D, Sotomayor EM (2007) Immunosuppressive strategies that are mediated by tumor cells. Annu Rev Immunol 25:267–296PubMedCrossRefGoogle Scholar
  12. 12.
    Kim S, Elkon KB, Ma X (2004) Transcriptional suppression of interleukin-12 gene expression following phagocytosis of apoptotic cells. Immunity 21(5):643–653PubMedCrossRefGoogle Scholar
  13. 13.
    Hoffmann PR, Kench JA, Vondracek A, Kruk E, Daleke DL, Jordan M, Marrack P, Henson PM, Fadok VA (2005) Interaction between phosphatidylserine and the phosphatidylserine receptor inhibits immune responses in vivo. J Immunol 174(3):1393–1404PubMedGoogle Scholar
  14. 14.
    Chen X, Doffek K, Sugg SL, Shilyansky J (2004) Phosphatidylserine regulates the maturation of human dendritic cells. J Immunol 173(5):2985–2994PubMedGoogle Scholar
  15. 15.
    Bondanza A, Zimmermann VS, Rovere-Querini P, Turnay J, Dumitriu IE, Stach CM, Voll RE, Gaipl US, Bertling W, Poschl E, Kalden JR, Manfredi AA, Herrmann M (2004) Inhibition of phosphatidylserine recognition heightens the immunogenicity of irradiated lymphoma cells in vivo. J Exp Med 200(9):1157–1165PubMedCrossRefGoogle Scholar
  16. 16.
    Williamson P, Schlegel RA (2002) Transbilayer phospholipid movement and the clearance of apoptotic cells. Biochim Biophys Acta 1585(2–3):53–63PubMedGoogle Scholar
  17. 17.
    Asano K, Miwa M, Miwa K, Hanayama R, Nagase H, Nagata S, Tanaka M (2004) Masking of phosphatidylserine inhibits apoptotic cell engulfment and induces autoantibody production in mice. J Exp Med 200(4):459–467PubMedCrossRefGoogle Scholar
  18. 18.
    Henson PM, Bratton DL, Fadok VA (2001) The phosphatidylserine receptor: a crucial molecular switch? Nat Rev Mol Cell Biol 2(8):627–633PubMedCrossRefGoogle Scholar
  19. 19.
    Gaipl US, Beyer TD, Baumann I, Voll RE, Stach CM, Heyder P, Kalden JR, Manfredi A, Herrmann M (2003) Exposure of anionic phospholipids serves as anti-inflammatory and immunosuppressive signal–implications for antiphospholipid syndrome and systemic lupus erythematosus. Immunobiology 207(1):73–81PubMedCrossRefGoogle Scholar
  20. 20.
    Pohl A, Lage H, Muller P, Pomorski T, Herrmann A (2002) Transport of phosphatidylserine via MDR1 (multidrug resistance 1)P- glycoprotein in a human gastric carcinoma cell line. Biochem J 365(Pt 1):259–268PubMedCrossRefGoogle Scholar
  21. 21.
    Woehlecke H, Pohl A, Alder-Baerens N, Lage H, Herrmann A (2003) Enhanced exposure of phosphatidylserine in human gastric carcinoma cells overexpressing the half-size ABC transporter BCRP (ABCG2). Biochem J 376(2):489–495PubMedCrossRefGoogle Scholar
  22. 22.
    Elliott JI, Surprenant A, Marelli-Berg FM, Cooper JC, Cassady-Cain RL, Wooding C, Linton K, Alexander DR, Higgins CF (2005) Membrane phosphatidylserine distribution as a non-apoptotic signalling mechanism in lymphocytes. Nat Cell Biol 7(8):808–816PubMedCrossRefGoogle Scholar
  23. 23.
    Hamon Y, Broccardo C, Chambenoit O, Luciani MF, Toti F, Chaslin S, Freyssinet JM, Devaux PF, McNeish J, Marguet D, Chimini G (2000) ABC1 promotes engulfment of apoptotic cells and transbilayer redistribution of phosphatidylserine. Nat Cell Biol 2(7):399–406PubMedCrossRefGoogle Scholar
  24. 24.
    Stach CM, Turnay X, Voll RE, Kern PM, Kolowos W, Beyer TD, Kalden JR, Herrmann M (2000) Treatment with annexin V increases immunogenicity of apoptotic human T-cells in Balb/c mice. Cell Death Differ 7(10):911–915PubMedCrossRefGoogle Scholar
  25. 25.
    Yan X, Johnson BD, Orentas RJ (2004) Murine CD8 lymphocyte expansion in vitro by artificial antigen-presenting cells expressing CD137L (4-1BBL) is superior to CD28, and CD137L expressed on neuroblastoma expands CD8 tumour-reactive effector cells in vivo. Immunology 112(1):105–116PubMedCrossRefGoogle Scholar
  26. 26.
    Jing W, Orentas RJ, Johnson BD (2007) Induction of immunity to neuroblastoma early after syngeneic hematopoietic stem cell transplantation using a novel mouse tumor vaccine. Biol Blood Marrow Transplant 13(3):277–292PubMedCrossRefGoogle Scholar
  27. 27.
    Johnson BD, Yan X, Schauer DW, Orentas RJ (2003) Dual expression of CD80 and CD86 produces a tumor vaccine superior to single expression of either molecule. Cell Immunol 222(1):15–26PubMedCrossRefGoogle Scholar
  28. 28.
    He J, Luster TA, Thorpe PE (2007) Radiation-enhanced vascular targeting of human lung cancers in mice with a monoclonal antibody that binds anionic phospholipids. Clin Cancer Res 13(17):5211–5218PubMedCrossRefGoogle Scholar
  29. 29.
    Wang RF, Miyahara Y, Wang HY (2008) Toll-like receptors and immune regulation: implications for cancer therapy. Oncogene 27(2):181–189PubMedCrossRefGoogle Scholar
  30. 30.
    Chen X, Doffek K, Sugg SL, Shilyansky J (2003) Neuroblastoma cells inhibit the immunostimulatory function of dendritic cells. J Pediatr Surg 38(6):901–905PubMedCrossRefGoogle Scholar
  31. 31.
    Shurin GV, Lotze MT, Barksdale EM (2000) Neuroblastoma inhibits dendritic cell differentiation and function. Curr Surg 57(6):637PubMedCrossRefGoogle Scholar
  32. 32.
    Horna P, Sotomayor EM (2007) Cellular and molecular mechanisms of tumor-induced T-cell tolerance. Curr Cancer Drug Targets 7(1):41–53PubMedCrossRefGoogle Scholar
  33. 33.
    Zhou G, Levitsky HI (2007) Natural regulatory T cells and de novo-induced regulatory T cells contribute independently to tumor-specific tolerance. J Immunol 178(4):2155–2162PubMedGoogle Scholar
  34. 34.
    Kim R, Emi M, Tanabe K (2005) Cancer cell immune escape and tumor progression by exploitation of anti-inflammatory and pro-inflammatory responses. Cancer Biol Ther 4(9):924–933PubMedCrossRefGoogle Scholar
  35. 35.
    Johnson BD, Gershan JA, Natalia N, Zujewski H, Weber JJ, Yan X, Orentas RJ (2005) Neuroblastoma cells transiently transfected to simultaneously express the co-stimulatory molecules CD54, CD80, CD86, and CD137L generate antitumor immunity in mice. J Immunother 28(5):449–460PubMedCrossRefGoogle Scholar
  36. 36.
    Kenis H, Hofstra L, Reutelingsperger CP (2007) Annexin A5: shifting from a diagnostic towards a therapeutic realm. Cell Mol Life Sci 64(22):2859–2862PubMedCrossRefGoogle Scholar
  37. 37.
    Ran S, Downes A, Thorpe PE (2002) Increased exposure of anionic phospholipids on the surface of tumor blood vessels. Cancer Res 62(21):6132–6140PubMedGoogle Scholar
  38. 38.
    Calderon C, Huang ZH, Gage DA, Sotomayor EM, Lopez DM (1994) Isolation of a nitric oxide inhibitor from mammary tumor cells and its characterization as phosphatidylserine. J Exp Med 180(3):945–958PubMedCrossRefGoogle Scholar
  39. 39.
    Fonseca C, Dranoff G (2008) Capitalizing on the immunogenicity of dying tumor cells. Clin Cancer Res 14(6):1603–1608PubMedCrossRefGoogle Scholar
  40. 40.
    Beck AW, Luster TA, Miller AF, Holloway SE, Conner CR, Barnett CC, Thorpe PE, Fleming JB, Brekken RA (2006) Combination of a monoclonal anti-phosphatidylserine antibody with gemcitabine strongly inhibits the growth and metastasis of orthotopic pancreatic tumors in mice. Int J Cancer 118(10):2639–2643PubMedCrossRefGoogle Scholar
  41. 41.
    He J, Yin Y, Luster TA, Watkins L, Thorpe PE (2009) Antiphosphatidylserine antibody combined with irradiation damages tumor blood vessels and induces tumor immunity in a rat model of glioblastoma. Clin Cancer Res 15(22):6871–6880PubMedCrossRefGoogle Scholar
  42. 42.
    Huynh ML, Fadok VA, Henson PM (2002) Phosphatidylserine-dependent ingestion of apoptotic cells promotes TGF-beta1 secretion and the resolution of inflammation. J Clin Invest 109(1):41–50PubMedGoogle Scholar
  43. 43.
    Freeman GJ, Casasnovas JM, Umetsu DT, DeKruyff RH (2010) TIM genes: a family of cell surface phosphatidylserine receptors that regulate innate and adaptive immunity. Immunol Rev 235(1):172–189PubMedGoogle Scholar
  44. 44.
    Kobayashi N, Karisola P, Pena-Cruz V, Dorfman DM, Jinushi M, Umetsu SE, Butte MJ, Nagumo H, Chernova I, Zhu B, Sharpe AH, Ito S, Dranoff G, Kaplan GG, Casasnovas JM, Umetsu DT, Dekruyff RH, Freeman GJ (2007) TIM-1 and TIM-4 glycoproteins bind phosphatidylserine and mediate uptake of apoptotic cells. Immunity 27(6):927–940PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag 2012

Authors and Affiliations

  • Xiaocai Yan
    • 3
  • Kara Doffek
    • 2
  • Chaobo Yin
    • 1
  • Michael Krein
    • 1
  • Michael Phillips
    • 2
  • Sonia L. Sugg
    • 1
  • Bryon Johnson
    • 3
  • Joel Shilyansky
    • 1
    Email author
  1. 1.Department of SurgeryCarver School of Medicine, University of IowaIowa CityUSA
  2. 2.Department of SurgeryMedical College of WisconsinMilwaukeeUSA
  3. 3.Department of PediatricsMedical College of WisconsinMilwaukeeUSA

Personalised recommendations